The global oligonucleotide synthesis market is projected to reach USD 8.53 billion by 2030, registering a CAGR of 13.21% from 2024 to 2030. The strong pipeline of oligonucleotide therapeutics in clinical trials, advancements in gene editing technologies, and increasing R&D spending by biotechnology companies are some of the major factors driving the market growth. ![Global Oligonucleotide Synthesis Market]( "Global Oligonucleotide Synthesis Market")
Oligonucleotide therapeutics participants are present in the late stages of clinical trials and are expected to be approved & commercialized over the forecast period. Companies have increased investments to develop oligonucleotide-based therapeutics. In October 2023, GSK plc and Arrowhead Pharmaceuticals announced a contract with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to assign GSK exclusive worldwide rights to develop and commercialize JNJ-3989. Janssen initially in-licensed JNJ-3989 (previously ARO-HBV) from Arrowhead in 2018. Similar initiatives by well-established pharmaceutical companies are anticipated to drive market growth over the forecast period.
Government bodies, such as the Centers for Medicaid & Medicare Services for labs, the Federal Trade Commission for marketing, and the FDA for kits & information, have played a key role in the success of genomics, as they have been involved in monitoring the safe, appropriate, and accurate application of genomics & genetic tests. International funding bodies, such as NIH and Wellcome Trust, are engaged in providing funds for genetic studies, which is expected to fuel genomic studies in developed and emerging economies.
In May 2021, the UK government announced a funding of USD 43.4 million (GBP 37 million) for genomics research and data-driven initiatives, delivered via the UK Functional Genomics Initiative and Genome UK Implementation Plan, which was started in September 2019. The Genome UK strategy will be implemented with the help of the Genomics England project, which will receive USD 19.9 million (GBP 17 million) to investigate the potential value of newborn sequencing.
Oligonucleotide therapeutics participants are present in the late stages of clinical trials and are expected to be approved & commercialized over the forecast period. Companies have increased investments to develop oligonucleotide-based therapeutics. In October 2023, GSK plc and Arrowhead Pharmaceuticals announced a contract with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to assign GSK exclusive worldwide rights to develop and commercialize JNJ-3989. Janssen initially in-licensed JNJ-3989 (previously ARO-HBV) from Arrowhead in 2018. Similar initiatives by well-established pharmaceutical companies are anticipated to drive market growth over the forecast period.
Government bodies, such as the Centers for Medicaid & Medicare Services for labs, the Federal Trade Commission for marketing, and the FDA for kits & information, have played a key role in the success of genomics, as they have been involved in monitoring the safe, appropriate, and accurate application of genomics & genetic tests. International funding bodies, such as NIH and Wellcome Trust, are engaged in providing funds for genetic studies, which is expected to fuel genomic studies in developed and emerging economies.
In May 2021, the UK government announced a funding of USD 43.4 million (GBP 37 million) for genomics research and data-driven initiatives, delivered via the UK Functional Genomics Initiative and Genome UK Implementation Plan, which was started in September 2019. The Genome UK strategy will be implemented with the help of the Genomics England project, which will receive USD 19.9 million (GBP 17 million) to investigate the potential value of newborn sequencing.
Oligonucleotide Synthesis Market Report Highlights
- Based on product & services, the service segment dominated the market with more than 37% share in 2023 owing to the growing demand for specialized services and increasing number of demands for outsourcing services
- Based on application, the PCR primers segment held the largest market share in 2023. Their crucial role in amplifying specific DNA or RNA sequences makes them an essential component of the market
- North America dominated the market owing to factors such as increasing the presence of key players, increasing demand for synthetic DNA & RNA sequences in various applications, and favorable regulatory scenario
- In May 2023, GenScript expanded its life sciences facility in Zhenjiang, Jiangsu, China, to offer a rapid, high-purity oligonucleotide and peptide synthesis service tailored for research & development as well as preclinical applications.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product & service
1.2.2. Application
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
1.2. Segment Definitions
1.2.1. Product & service
1.2.2. Application
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Landscape Insights
2.2. Segment Outlook
2.3. Competitive Landscape Insights
Chapter 3. Oligonucleotide Synthesis Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Strong pipeline of oligonucleotide therapeutics in clinical trials
3.2.1.2. Changing regulatory environments for genetic research and its applications in healthcare
3.2.1.3. High R&D spending of pharmaceutical & biotechnology companies
3.2.1.4. Increased public-private spending on genomics
3.2.1.5. Technological advancements in gene editing technologies
3.2.2. Market restraint analysis
3.2.2.1. Need for advanced oligo synthesis solutions
3.2.2.2. High cost associated with genomics research
3.2.2.3. Lack of skilled professionals and research support in undeveloped countries
3.3. Business Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Strong pipeline of oligonucleotide therapeutics in clinical trials
3.2.1.2. Changing regulatory environments for genetic research and its applications in healthcare
3.2.1.3. High R&D spending of pharmaceutical & biotechnology companies
3.2.1.4. Increased public-private spending on genomics
3.2.1.5. Technological advancements in gene editing technologies
3.2.2. Market restraint analysis
3.2.2.1. Need for advanced oligo synthesis solutions
3.2.2.2. High cost associated with genomics research
3.2.2.3. Lack of skilled professionals and research support in undeveloped countries
3.3. Business Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Oligonucleotide Synthesis Market: Product & Service Estimates & Trend Analysis
4.1. Product & Service Market Share, 2023 & 2030
4.2. Market Size & Forecasts and Trend Analyses, 2018 to 2030
4.2.1. Oligonucleotides
4.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.1.2. DNA
4.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.1.2.2. Column-based
4.2.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.1.2.3. Array-based
4.2.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.1.3. RNA
4.2.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.1.3.2. By Technology
4.2.1.3.2.1. Column-based
4.2.1.3.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.1.3.2.2. Array-based
4.2.1.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.1.3.3. By Type
4.2.1.3.3.1. Short RNA Oligos (< 65 nt)
4.2.1.3.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.1.3.3.2. Long RNA Oligos (>65 nt)
4.2.1.3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.1.3.3.3. CRISPR (sgRNA)
4.2.1.3.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.2. Equipment/Synthesizer
4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.3. Reagents
4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4. Services
4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.2. DNA
4.2.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.2.2. Custom oligo synthesis services
4.2.4.2.2.1. 25 nmol
4.2.4.2.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.2.2.2. 50 nmol
4.2.4.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.2.2.3. 200 nmol
4.2.4.2.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.2.2.4. 1000 nmol
4.2.4.2.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.2.2.5. 10000 nmol
4.2.4.2.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.2.3. Modification services
4.2.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.2.4. Purification services
4.2.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.3. RNA
4.2.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.3.2. Custom oligo synthesis services
4.2.4.3.2.1. 25 nmol
4.2.4.3.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.3.2.2. 100 nmol
4.2.4.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.3.2.3. 1000 nmol
4.2.4.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.3.2.4. 10000 nmol
4.2.4.3.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.3.3. Modification services
4.2.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.3.4. Purification services
4.2.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2. Market Size & Forecasts and Trend Analyses, 2018 to 2030
4.2.1. Oligonucleotides
4.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.1.2. DNA
4.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.1.2.2. Column-based
4.2.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.1.2.3. Array-based
4.2.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.1.3. RNA
4.2.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.1.3.2. By Technology
4.2.1.3.2.1. Column-based
4.2.1.3.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.1.3.2.2. Array-based
4.2.1.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.1.3.3. By Type
4.2.1.3.3.1. Short RNA Oligos (< 65 nt)
4.2.1.3.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.1.3.3.2. Long RNA Oligos (>65 nt)
4.2.1.3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.1.3.3.3. CRISPR (sgRNA)
4.2.1.3.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.2. Equipment/Synthesizer
4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.3. Reagents
4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4. Services
4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.2. DNA
4.2.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.2.2. Custom oligo synthesis services
4.2.4.2.2.1. 25 nmol
4.2.4.2.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.2.2.2. 50 nmol
4.2.4.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.2.2.3. 200 nmol
4.2.4.2.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.2.2.4. 1000 nmol
4.2.4.2.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.2.2.5. 10000 nmol
4.2.4.2.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.2.3. Modification services
4.2.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.2.4. Purification services
4.2.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.3. RNA
4.2.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.3.2. Custom oligo synthesis services
4.2.4.3.2.1. 25 nmol
4.2.4.3.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.3.2.2. 100 nmol
4.2.4.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.3.2.3. 1000 nmol
4.2.4.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.3.2.4. 10000 nmol
4.2.4.3.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.3.3. Modification services
4.2.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.2.4.3.4. Purification services
4.2.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Oligonucleotide Synthesis Market: Application Estimates & Trend Analysis
5.1. Application Market Share, 2023 & 2030
5.2. Market Size & Forecasts and Trend Analyses, 2018 to 2030
5.2.1. PCR primers
5.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.1.2. Academic research institutes
5.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.1.2.2. Diagnostic laboratories
5.2.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.1.2.3. Pharmaceutical - biotechnology companies
5.2.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.2. PCR assays and panels
5.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.2.2. Academic research institutes
5.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.2.2.2. Diagnostic laboratories
5.2.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.2.2.3. Pharmaceutical - biotechnology companies
5.2.2.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.3. Sequencing
5.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.3.2. Academic research institutes
5.2.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.3.2.2. Diagnostic laboratories
5.2.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.3.2.3. Pharmaceutical - biotechnology companies
5.2.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.4. DNA microarrays
5.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.4.2. Academic research institutes
5.2.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.4.2.2. Diagnostic laboratories
5.2.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.4.2.3. Pharmaceutical - biotechnology companies
5.2.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.5. Fluorescence in situ hybridization (FISH)
5.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.5.2. Academic research institutes
5.2.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.5.2.2. Diagnostic laboratories
5.2.5.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.5.2.3. Pharmaceutical - biotechnology companies
5.2.5.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.6. Antisense oligonucleotides
5.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.6.2. Academic research institutes
5.2.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.6.2.2. Diagnostic laboratories
5.2.6.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.6.2.3. Pharmaceutical - biotechnology companies
5.2.6.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.7. Other applications
5.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2. Market Size & Forecasts and Trend Analyses, 2018 to 2030
5.2.1. PCR primers
5.2.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.1.2. Academic research institutes
5.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.1.2.2. Diagnostic laboratories
5.2.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.1.2.3. Pharmaceutical - biotechnology companies
5.2.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.2. PCR assays and panels
5.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.2.2. Academic research institutes
5.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.2.2.2. Diagnostic laboratories
5.2.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.2.2.3. Pharmaceutical - biotechnology companies
5.2.2.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.3. Sequencing
5.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.3.2. Academic research institutes
5.2.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.3.2.2. Diagnostic laboratories
5.2.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.3.2.3. Pharmaceutical - biotechnology companies
5.2.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.4. DNA microarrays
5.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.4.2. Academic research institutes
5.2.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.4.2.2. Diagnostic laboratories
5.2.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.4.2.3. Pharmaceutical - biotechnology companies
5.2.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.5. Fluorescence in situ hybridization (FISH)
5.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.5.2. Academic research institutes
5.2.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.5.2.2. Diagnostic laboratories
5.2.5.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.5.2.3. Pharmaceutical - biotechnology companies
5.2.5.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.6. Antisense oligonucleotides
5.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.6.2. Academic research institutes
5.2.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.6.2.2. Diagnostic laboratories
5.2.6.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.6.2.3. Pharmaceutical - biotechnology companies
5.2.6.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2.7. Other applications
5.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Oligonucleotide Synthesis Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2023 & 2030
6.2. North America
6.2.1. U.S.
6.2.1.1. Key country dynamics
6.2.1.2. Regulatory framework
6.2.1.3. Competitive scenario
6.2.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.2.2. Canada
6.2.2.1. Key country dynamics
6.2.2.2. Regulatory framework
6.2.2.3. Competitive scenario
6.2.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.3. Europe
6.3.1. UK
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework
6.3.1.3. Competitive scenario
6.3.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.3.2. Germany
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework
6.3.2.3. Competitive scenario
6.3.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.3.3. France
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework
6.3.3.3. Competitive scenario
6.3.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.3.4. Italy
6.3.4.1. Key country dynamics
6.3.4.2. Regulatory framework
6.3.4.3. Competitive scenario
6.3.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.3.5. Spain
6.3.5.1. Key country dynamics
6.3.5.2. Regulatory framework
6.3.5.3. Competitive scenario
6.3.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.3.6. Norway
6.3.6.1. Key country dynamics
6.3.6.2. Regulatory framework
6.3.6.3. Competitive scenario
6.3.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.3.7. Sweden
6.3.7.1. Key country dynamics
6.3.7.2. Regulatory framework
6.3.7.3. Competitive scenario
6.3.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.3.8. Denmark
6.3.8.1. Key country dynamics
6.3.8.2. Regulatory framework
6.3.8.3. Competitive scenario
6.3.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.4. Asia-Pacific
6.4.1. Japan
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework
6.4.1.3. Competitive scenario
6.4.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. China
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework
6.4.2.3. Competitive scenario
6.4.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. India
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework
6.4.3.3. Competitive scenario
6.4.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Australia
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework
6.4.4.3. Competitive scenario
6.4.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.4.5. South Korea
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework
6.4.5.3. Competitive scenario
6.4.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.4.6. Thailand
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework
6.4.6.3. Competitive scenario
6.4.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Latin America
6.5.1. Brazil
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework
6.5.1.3. Competitive scenario
6.5.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. Mexico
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework
6.5.2.3. Competitive scenario
6.5.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. Argentina
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework
6.5.3.3. Competitive scenario
6.5.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.6. MEA
6.6.1. South Africa
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework
6.6.1.3. Competitive scenario
6.6.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. Saudi Arabia
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework
6.6.2.3. Competitive scenario
6.6.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.6.3. UAE
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework
6.6.3.3. Competitive scenario
6.6.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.6.4. Kuwait
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework
6.6.4.3. Competitive scenario
6.6.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
6.2. North America
6.2.1. U.S.
6.2.1.1. Key country dynamics
6.2.1.2. Regulatory framework
6.2.1.3. Competitive scenario
6.2.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.2.2. Canada
6.2.2.1. Key country dynamics
6.2.2.2. Regulatory framework
6.2.2.3. Competitive scenario
6.2.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.3. Europe
6.3.1. UK
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework
6.3.1.3. Competitive scenario
6.3.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.3.2. Germany
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework
6.3.2.3. Competitive scenario
6.3.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.3.3. France
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework
6.3.3.3. Competitive scenario
6.3.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.3.4. Italy
6.3.4.1. Key country dynamics
6.3.4.2. Regulatory framework
6.3.4.3. Competitive scenario
6.3.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.3.5. Spain
6.3.5.1. Key country dynamics
6.3.5.2. Regulatory framework
6.3.5.3. Competitive scenario
6.3.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.3.6. Norway
6.3.6.1. Key country dynamics
6.3.6.2. Regulatory framework
6.3.6.3. Competitive scenario
6.3.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.3.7. Sweden
6.3.7.1. Key country dynamics
6.3.7.2. Regulatory framework
6.3.7.3. Competitive scenario
6.3.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.3.8. Denmark
6.3.8.1. Key country dynamics
6.3.8.2. Regulatory framework
6.3.8.3. Competitive scenario
6.3.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.4. Asia-Pacific
6.4.1. Japan
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework
6.4.1.3. Competitive scenario
6.4.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. China
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework
6.4.2.3. Competitive scenario
6.4.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. India
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework
6.4.3.3. Competitive scenario
6.4.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Australia
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework
6.4.4.3. Competitive scenario
6.4.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.4.5. South Korea
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework
6.4.5.3. Competitive scenario
6.4.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.4.6. Thailand
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework
6.4.6.3. Competitive scenario
6.4.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Latin America
6.5.1. Brazil
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework
6.5.1.3. Competitive scenario
6.5.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. Mexico
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework
6.5.2.3. Competitive scenario
6.5.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. Argentina
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework
6.5.3.3. Competitive scenario
6.5.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.6. MEA
6.6.1. South Africa
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework
6.6.1.3. Competitive scenario
6.6.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. Saudi Arabia
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework
6.6.2.3. Competitive scenario
6.6.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.6.3. UAE
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework
6.6.3.3. Competitive scenario
6.6.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.6.4. Kuwait
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework
6.6.4.3. Competitive scenario
6.6.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company/Competition Categorization
7.2. Strategy Mapping
7.3. Company Market Position Analysis, 2023
7.4. Company Profiles/Listing
7.4.1. Thermo Fisher Scientific, Inc.
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Merck KGaA
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. Danaher Corporation
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Dharmacon Inc.
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Agilent Technologies
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Bio-synthesis
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Kaneka Eurogentec S.A
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. LGC Biosearch Technologies
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Biolegio
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. Twist Bioscience
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives
7.2. Strategy Mapping
7.3. Company Market Position Analysis, 2023
7.4. Company Profiles/Listing
7.4.1. Thermo Fisher Scientific, Inc.
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Merck KGaA
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. Danaher Corporation
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Dharmacon Inc.
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Agilent Technologies
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Bio-synthesis
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Kaneka Eurogentec S.A
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. LGC Biosearch Technologies
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Biolegio
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. Twist Bioscience
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 Global oligonucleotide synthesis market, by region, 2018-2030 (USD Million)
Table 3 North America oligonucleotide synthesis market, by country, 2018-2030 (USD Million)
Table 4 North America oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 5 North America oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 6 U.S. oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 7 U.S. oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 8 Canada oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 9 Canada oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 10 Europe oligonucleotide synthesis market, by country, 2018-2030 (USD Million)
Table 11 Europe oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 12 Europe oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 13 Germany oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 14 Germany oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 15 UK oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 16 UK oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 17 France oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 18 France oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 19 Italy oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 20 Italy oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 21 Spain oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 22 Spain oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 23 Denmark oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 24 Denmark oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 25 Sweden oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 26 Sweden oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 27 Norway oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 28 Norway oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 29 Asia-Pacific oligonucleotide synthesis market, by country, 2018-2030 (USD Million)
Table 30 Asia-Pacific oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 31 Asia-Pacific oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 32 China oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 33 China oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 34 Japan oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 35 Japan oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 36 India oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 37 India oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 38 South Korea oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 39 South Korea oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 40 Australia oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 41 Australia oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 42 Thailand oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 43 Thailand oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 44 Latin America oligonucleotide synthesis market, by country, 2018-2030 (USD Million)
Table 45 Latin America oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 46 Latin America oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 47 Brazil oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 48 Brazil oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 49 Mexico oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 50 Mexico oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 51 Argentina oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 52 Argentina oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 53 MEA oligonucleotide synthesis market, by country, 2018-2030 (USD Million)
Table 54 MEA oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 55 MEA oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 56 South Africa oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 57 South Africa oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 58 Saudi Arabia oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 59 Saudi Arabia oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 60 UAE oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 61 UAE oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 62 Kuwait oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 63 Kuwait oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 2 Global oligonucleotide synthesis market, by region, 2018-2030 (USD Million)
Table 3 North America oligonucleotide synthesis market, by country, 2018-2030 (USD Million)
Table 4 North America oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 5 North America oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 6 U.S. oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 7 U.S. oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 8 Canada oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 9 Canada oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 10 Europe oligonucleotide synthesis market, by country, 2018-2030 (USD Million)
Table 11 Europe oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 12 Europe oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 13 Germany oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 14 Germany oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 15 UK oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 16 UK oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 17 France oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 18 France oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 19 Italy oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 20 Italy oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 21 Spain oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 22 Spain oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 23 Denmark oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 24 Denmark oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 25 Sweden oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 26 Sweden oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 27 Norway oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 28 Norway oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 29 Asia-Pacific oligonucleotide synthesis market, by country, 2018-2030 (USD Million)
Table 30 Asia-Pacific oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 31 Asia-Pacific oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 32 China oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 33 China oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 34 Japan oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 35 Japan oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 36 India oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 37 India oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 38 South Korea oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 39 South Korea oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 40 Australia oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 41 Australia oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 42 Thailand oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 43 Thailand oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 44 Latin America oligonucleotide synthesis market, by country, 2018-2030 (USD Million)
Table 45 Latin America oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 46 Latin America oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 47 Brazil oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 48 Brazil oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 49 Mexico oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 50 Mexico oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 51 Argentina oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 52 Argentina oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 53 MEA oligonucleotide synthesis market, by country, 2018-2030 (USD Million)
Table 54 MEA oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 55 MEA oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 56 South Africa oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 57 South Africa oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 58 Saudi Arabia oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 59 Saudi Arabia oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 60 UAE oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 61 UAE oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
Table 62 Kuwait oligonucleotide synthesis market, by product & service, 2018-2030 (USD Million)
Table 63 Kuwait oligonucleotide synthesis market, by application, 2018-2030 (USD Million)
List of Figures
Fig. 1 Oligonucleotide synthesis market segmentation
Fig. 2 Data analysis models
Fig. 3 Market formulation and validation
Fig. 4 Data validating & publishing
Fig. 5 Market research process
Fig. 6 Information procurement
Fig. 7 Primary research
Fig. 8 Value-chain-based sizing & forecasting
Fig. 9 QFD modelling for market share assessment
Fig. 10 Market formulation & validation
Fig. 11 Commodity flow analysis
Fig. 12 Market outlook
Fig. 13 Segment snapshot
Fig. 14 Competitive landscape snapshot
Fig. 15 Synthetic biology market value, 2023 (USD billion)
Fig. 16 Market trends & outlook
Fig. 17 Top investors in drug R&D as a percentage of net sales (2019)
Fig. 18 PESTEL analysis
Fig. 19 Porter’s five forces analysis
Fig. 20 Oligonucleotide synthesis market: Product & service outlook & key takeaways
Fig. 21 Oligonucleotide synthesis market: Product & service movement analysis
Fig. 22 Oligonucleotides market estimates and forecasts, 2018-2030 (USD Million)
Fig. 23 DNA market estimates and forecasts, 2018-2030 (USD Million)
Fig. 24 Column-based market estimates and forecasts, 2018-2030 (USD Million)
Fig. 25 Array-based market estimates and forecasts, 2018-2030 (USD Million)
Fig. 26 RNA market estimates and forecasts, 2018-2030 (USD Million)
Fig. 27 Column-based market estimates and forecasts, 2018-2030 (USD Million)
Fig. 28 Array-based market estimates and forecasts, 2018-2030 (USD Million)
Fig. 29 Short RNA oligos (< 65 nt) market estimates and forecasts, 2018-2030 (USD Million)
Fig. 30 Long RNA oligos (>65 nt) market estimates and forecasts, 2018-2030 (USD Million)
Fig. 31 CRISPR (sgRNA) market estimates and forecasts, 2018-2030 (USD Million)
Fig. 32 Equipment/synthesizer market estimates and forecasts, 2018-2030 (USD Million)
Fig. 33 Reagents market estimates and forecasts, 2018-2030 (USD Million)
Fig. 34 Services market estimates and forecasts, 2018-2030 (USD Million)
Fig. 35 DNA market estimates and forecasts, 2018-2030 (USD Million)
Fig. 36 Custom oligo synthesis services market estimates and forecasts, 2018-2030 (USD Million)
Fig. 37 25 nmol market estimates and forecasts, 2018-2030 (USD Million)
Fig. 38 50 nmol market estimates and forecasts, 2018-2030 (USD Million)
Fig. 39 200 nmol market estimates and forecasts, 2018-2030 (USD Million)
Fig. 40 1,000 nmol market estimates and forecasts, 2018-2030 (USD Million)
Fig. 41 10,000 nmol market estimates and forecasts, 2018-2030 (USD Million)
Fig. 42 Modification services market estimates and forecasts, 2018-2030 (USD Million)
Fig. 43 Purification services market estimates and forecasts, 2018-2030 (USD Million)
Fig. 44 RNA market estimates and forecasts, 2018-2030 (USD Million)
Fig. 45 Custom oligo synthesis services market estimates and forecasts, 2018-2030 (USD Million)
Fig. 46 25 nmol market estimates and forecasts, 2018-2030 (USD Million)
Fig. 47 100 nmol market estimates and forecasts, 2018-2030 (USD Million)
Fig. 48 1,000 nmol market estimates and forecasts, 2018-2030 (USD Million)
Fig. 49 10,000 nmol market estimates and forecasts, 2018-2030 (USD Million)
Fig. 50 Modification services market estimates and forecasts, 2018-2030 (USD Million)
Fig. 51 Purification services market estimates and forecasts, 2018-2030 (USD Million)
Fig. 52 Oligonucleotide synthesis market: Application outlook & key takeaways
Fig. 53 Oligonucleotide synthesis market: Application movement analysis
Fig. 54 PCR primers market estimates and forecasts, 2018-2030 (USD Million)
Fig. 55 PCR assays and panels market estimates and forecasts, 2018-2030 (USD Million)
Fig. 56 Sequencing market estimates and forecasts, 2018-2030 (USD Million)
Fig. 57 DNA microarrays market estimates and forecasts, 2018-2030 (USD Million)
Fig. 58 Fluorescence In Situ Hybridization (FISH) market estimates and forecasts, 2018-2030 (USD Million)
Fig. 59 Antisense oligonucleotides market estimates and forecasts, 2018-2030 (USD Million)
Fig. 60 Other applications market estimates and forecasts, 2018-2030 (USD Million)
Fig. 61 Regional marketplace outlook, 2023 & 2030, (USD Million)
Fig. 62 Regional marketplace: Key takeaways
Fig. 63 North America oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 64 U.S. key country dynamics
Fig. 65 U.S. oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 66 Canada key country dynamics
Fig. 67 Canada oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 68 Europe oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 69 UK key country dynamics
Fig. 70 UK oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 71 Germany key country dynamics
Fig. 72 Germany oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 73 France key country dynamics
Fig. 74 France oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 75 Spain key country dynamics
Fig. 76 Spain oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 77 Italy key country dynamics
Fig. 78 Italy oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 79 Denmark key country dynamics
Fig. 80 Denmark oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 81 Sweden key country dynamics
Fig. 82 Sweden oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 83 Norway key country dynamics
Fig. 84 Norway oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 85 Asia-Pacific oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 86 Japan key country dynamics
Fig. 87 Japan oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 88 China key country dynamics
Fig. 89 China oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 90 India key country dynamics
Fig. 91 India oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 92 Australia Key country dynamics
Fig. 93 Australia oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 94 Thailand key country dynamics
Fig. 95 Thailand oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 96 South Korea key country dynamics
Fig. 97 South Korea oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 98 Latin America oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 99 Brazil key country dynamics
Fig. 100 Brazil oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 101 Mexico key country dynamics
Fig. 102 Mexico oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 103 Argentina key country dynamics
Fig. 104 Argentina oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 105 MEA oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 106 South Africa key country dynamics
Fig. 107 South Africa oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 108 Saudi Arabia key country dynamics
Fig. 109 Saudi Arabia oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 110 UAE key country dynamics
Fig. 111 UAE oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 112 Kuwait key country dynamics
Fig. 113 Kuwait oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 114 Market participant categorization
Fig. 115 Global oligonucleotide synthesis market position analysis, 2023
Fig. 116 Strategic framework
Fig. 2 Data analysis models
Fig. 3 Market formulation and validation
Fig. 4 Data validating & publishing
Fig. 5 Market research process
Fig. 6 Information procurement
Fig. 7 Primary research
Fig. 8 Value-chain-based sizing & forecasting
Fig. 9 QFD modelling for market share assessment
Fig. 10 Market formulation & validation
Fig. 11 Commodity flow analysis
Fig. 12 Market outlook
Fig. 13 Segment snapshot
Fig. 14 Competitive landscape snapshot
Fig. 15 Synthetic biology market value, 2023 (USD billion)
Fig. 16 Market trends & outlook
Fig. 17 Top investors in drug R&D as a percentage of net sales (2019)
Fig. 18 PESTEL analysis
Fig. 19 Porter’s five forces analysis
Fig. 20 Oligonucleotide synthesis market: Product & service outlook & key takeaways
Fig. 21 Oligonucleotide synthesis market: Product & service movement analysis
Fig. 22 Oligonucleotides market estimates and forecasts, 2018-2030 (USD Million)
Fig. 23 DNA market estimates and forecasts, 2018-2030 (USD Million)
Fig. 24 Column-based market estimates and forecasts, 2018-2030 (USD Million)
Fig. 25 Array-based market estimates and forecasts, 2018-2030 (USD Million)
Fig. 26 RNA market estimates and forecasts, 2018-2030 (USD Million)
Fig. 27 Column-based market estimates and forecasts, 2018-2030 (USD Million)
Fig. 28 Array-based market estimates and forecasts, 2018-2030 (USD Million)
Fig. 29 Short RNA oligos (< 65 nt) market estimates and forecasts, 2018-2030 (USD Million)
Fig. 30 Long RNA oligos (>65 nt) market estimates and forecasts, 2018-2030 (USD Million)
Fig. 31 CRISPR (sgRNA) market estimates and forecasts, 2018-2030 (USD Million)
Fig. 32 Equipment/synthesizer market estimates and forecasts, 2018-2030 (USD Million)
Fig. 33 Reagents market estimates and forecasts, 2018-2030 (USD Million)
Fig. 34 Services market estimates and forecasts, 2018-2030 (USD Million)
Fig. 35 DNA market estimates and forecasts, 2018-2030 (USD Million)
Fig. 36 Custom oligo synthesis services market estimates and forecasts, 2018-2030 (USD Million)
Fig. 37 25 nmol market estimates and forecasts, 2018-2030 (USD Million)
Fig. 38 50 nmol market estimates and forecasts, 2018-2030 (USD Million)
Fig. 39 200 nmol market estimates and forecasts, 2018-2030 (USD Million)
Fig. 40 1,000 nmol market estimates and forecasts, 2018-2030 (USD Million)
Fig. 41 10,000 nmol market estimates and forecasts, 2018-2030 (USD Million)
Fig. 42 Modification services market estimates and forecasts, 2018-2030 (USD Million)
Fig. 43 Purification services market estimates and forecasts, 2018-2030 (USD Million)
Fig. 44 RNA market estimates and forecasts, 2018-2030 (USD Million)
Fig. 45 Custom oligo synthesis services market estimates and forecasts, 2018-2030 (USD Million)
Fig. 46 25 nmol market estimates and forecasts, 2018-2030 (USD Million)
Fig. 47 100 nmol market estimates and forecasts, 2018-2030 (USD Million)
Fig. 48 1,000 nmol market estimates and forecasts, 2018-2030 (USD Million)
Fig. 49 10,000 nmol market estimates and forecasts, 2018-2030 (USD Million)
Fig. 50 Modification services market estimates and forecasts, 2018-2030 (USD Million)
Fig. 51 Purification services market estimates and forecasts, 2018-2030 (USD Million)
Fig. 52 Oligonucleotide synthesis market: Application outlook & key takeaways
Fig. 53 Oligonucleotide synthesis market: Application movement analysis
Fig. 54 PCR primers market estimates and forecasts, 2018-2030 (USD Million)
Fig. 55 PCR assays and panels market estimates and forecasts, 2018-2030 (USD Million)
Fig. 56 Sequencing market estimates and forecasts, 2018-2030 (USD Million)
Fig. 57 DNA microarrays market estimates and forecasts, 2018-2030 (USD Million)
Fig. 58 Fluorescence In Situ Hybridization (FISH) market estimates and forecasts, 2018-2030 (USD Million)
Fig. 59 Antisense oligonucleotides market estimates and forecasts, 2018-2030 (USD Million)
Fig. 60 Other applications market estimates and forecasts, 2018-2030 (USD Million)
Fig. 61 Regional marketplace outlook, 2023 & 2030, (USD Million)
Fig. 62 Regional marketplace: Key takeaways
Fig. 63 North America oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 64 U.S. key country dynamics
Fig. 65 U.S. oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 66 Canada key country dynamics
Fig. 67 Canada oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 68 Europe oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 69 UK key country dynamics
Fig. 70 UK oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 71 Germany key country dynamics
Fig. 72 Germany oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 73 France key country dynamics
Fig. 74 France oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 75 Spain key country dynamics
Fig. 76 Spain oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 77 Italy key country dynamics
Fig. 78 Italy oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 79 Denmark key country dynamics
Fig. 80 Denmark oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 81 Sweden key country dynamics
Fig. 82 Sweden oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 83 Norway key country dynamics
Fig. 84 Norway oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 85 Asia-Pacific oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 86 Japan key country dynamics
Fig. 87 Japan oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 88 China key country dynamics
Fig. 89 China oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 90 India key country dynamics
Fig. 91 India oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 92 Australia Key country dynamics
Fig. 93 Australia oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 94 Thailand key country dynamics
Fig. 95 Thailand oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 96 South Korea key country dynamics
Fig. 97 South Korea oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 98 Latin America oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 99 Brazil key country dynamics
Fig. 100 Brazil oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 101 Mexico key country dynamics
Fig. 102 Mexico oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 103 Argentina key country dynamics
Fig. 104 Argentina oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 105 MEA oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 106 South Africa key country dynamics
Fig. 107 South Africa oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 108 Saudi Arabia key country dynamics
Fig. 109 Saudi Arabia oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 110 UAE key country dynamics
Fig. 111 UAE oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 112 Kuwait key country dynamics
Fig. 113 Kuwait oligonucleotide synthesis market estimates and forecasts, 2018-2030 (USD Million)
Fig. 114 Market participant categorization
Fig. 115 Global oligonucleotide synthesis market position analysis, 2023
Fig. 116 Strategic framework
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Merck KGaA
- Danaher Corporation
- Dharmacon Inc.
- Agilent Technologies
- Bio-synthesis
- Kaneka Eurogentec S.A
- LGC Biosearch Technologies
- Biolegio
- Twist Bioscience
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 135 |
| Published | January 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 3.68 Billion |
| Forecasted Market Value ( USD | $ 8.53 Billion |
| Compound Annual Growth Rate | 13.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
